Blue Jet Healthcare Ltd Q1 FY26 Earnings Analysis

- Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 crore per quarter. - Contrast media segment depressed in H1 FY'25 but rebounded in H2; new product validations including NCE molecules contributing to growth expected in FY'26 and FY'27 (e.g., iodinated intermediate expected to ramp up fully in FY'27). - PI-API segment grew by 388% YoY, driven by advanced intermediates in cardiovascular therapy; order book fully served with new capacity at Ambernath. - Europe and Latin America markets for cardiovascular molecules growing faster than in the US. - Overall revenue grew 45% in FY'25; company aims to sustain growth momentum with strong customer demand, multi-year contracts, and capacity headroom. - No forward guidance on exact numbers, but linear growth and high single-digit growth anticipated from key products. - New capacities (Mahad Unit-3) expected online by H2 FY'26, supporting further ramp-up.

- Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum. - Management expects continued growth driven by ramp-up in pharma intermediates and API segments, with advanced intermediates and cardiovascular molecules scaling up further in FY'26. - New product validations in contrast media and launch of iodinated intermediate expected to add growth from H1 FY'26, with full potential visible in FY'27. - EBITDA margins improved to 37%; no forward guidance given, but operational leverage and cost discipline should further improve margins. - Capacity expansions at Ambernath, Mahad Unit-3 (backward integration), and new Dahej site to support future volume growth. - EPS doubled in FY'25 to ₹17.59, suggesting strong earnings growth potential aligned with capacity additions and product ramp-ups.

- Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad. - Additional capacity being built at Mahad Unit-3, a continuous plant for KSM making, expected to go live in H2 FY'26. - Multipurpose Plant (MPP) under construction in Mahad, highly automated with ~30 reactors, capacity expected by second half of FY'27; CAPEX for MPP revised upwards to ~Rs. 300 crores. - State-of-the-art R&D center being built in Hyderabad at Rs. 40 crores, focusing on peptides, GLP-1 intermediates, biocatalysts. - Acquisition of land in GIDC Dahej, Gujarat for further expansion for CMI and pharma intermediates; timelines not yet firm. - Process excellence initiative at Unit-2 with Rs. 60 crores committed for solvent recovery units to reduce waste and improve recycling. - Overall CAPEX strategy aligned with client lock-ins, demand visibility from new molecules, and supply chain resilience efforts.

- Blue Jet Healthcare Limited indicated plans for fundraising related to a Rs. 1500 crore number mentioned in announcements. - The exact details, including how much they intend to raise, have not been finalized or disclosed yet. - Shiven Arora mentioned that more visibility on the fundraising plans would be shared in the immediate upcoming quarter. - Although the decision to raise funds has been made, the company is not yet in a position to disclose specific details. - No clear distinction was provided on whether the fundraising will be through debt, equity, or a combination.

- The current order book for pharma intermediates is fully served with new capacity added at Ambernath, resulting in a 388% jump compared to FY'24. - Supplies for an NCE molecule started in Q4, with expected linear order book growth aligned with this molecule's growth. - The iodinated intermediate is expected to launch in H1 FY'26, with full potential realization anticipated in FY'27. - Discussions with customers provide good demand visibility; the Company bases volume supply on these forecasts, not on external speculations. - Cardiovascular intermediate capacity utilization is about 60%-65%, indicating room for growth and readiness to capture demand upticks. - Ongoing capacity expansion at Mahad (Unit-3) will enhance supply, aiming for validation and commercial production in H2 FY'26. - Active discussions and contracts are ongoing with key customers (Esperion, Daiichi) for pharmaceutical products supply.